Verified peer comparison

REGN vs GILD

Regeneron Pharmaceuticals, Inc. compared with Gilead Sciences, Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

REGN

Regeneron Pharmaceuticals, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

GILD

Gilead Sciences, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

REGN: Biotechnology

GILD: Biotechnology

Upside lens

REGN: New indications, age groups and geographies can extend a broad type-2 inflammation franchise. Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry. Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

GILD: Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Risk lens

REGN: Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share. Profit-sharing and dependence on collaborators shape the cash economics of major products. Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

GILD: Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

Verified sources

Regeneron Reports First Quarter 2026 Financial and Operating ResultsRegeneron Pharmaceuticals, Inc. · earningsVerified